InvestorsHub Logo
Followers 829
Posts 119691
Boards Moderated 16
Alias Born 09/05/2002

Re: jmkobers post# 677

Tuesday, 03/19/2019 1:42:48 PM

Tuesday, March 19, 2019 1:42:48 PM

Post# of 7528
Re: Hugel

The “other” possible entrant that post is referring to is presumably Hugel’s Botulax, which is approved in Korea and Taiwan (http://www.theinvestor.co.kr/view.php?ud=20181204000586 ).

The US development rights to Botulax are owned by a JV of Hugel and an Austrian company called Choma-Pharma (http://www.theinvestor.co.kr/view.php?ud=20181204000586 ); however, it’s unclear whether—or when—this JV might make a serious attempt to bring Botulax to the US market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RVNC News